Evaxion Biotech AS (EVAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evaxion Biotech AS (EVAX) has a cash flow conversion efficiency ratio of -0.390x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.65 Million) by net assets ($17.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See EVAX equity to assets ratio to measure how much of total assets are equity-financed.
Evaxion Biotech AS - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Evaxion Biotech AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore EVAX debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Evaxion Biotech AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evaxion Biotech AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YBM Net Inc
KQ:057030
|
0.071x |
|
Cleanspace Holdings Ltd
AU:CSX
|
-0.017x |
|
Wolftank Group AG
XETRA:WAH
|
0.157x |
|
TPC Mechatronics Corporation
KQ:048770
|
-0.016x |
|
Parkway Corporate Ltd
AU:PWN
|
-0.011x |
|
Naos Emerging Opportunities Company Ltd
AU:NCC
|
0.055x |
|
UTStarcom Holdings Corp
NASDAQ:UTSI
|
-0.054x |
|
Mount Ridley Mines Ltd
AU:MRD
|
-0.269x |
Annual Cash Flow Conversion Efficiency for Evaxion Biotech AS (2018–2025)
The table below shows the annual cash flow conversion efficiency of Evaxion Biotech AS from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Evaxion Biotech AS stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.04 Million | $-6.65 Million | -0.390x | -104.98% |
| 2024-12-31 | $-1.65 Million | $-12.94 Million | 7.833x | +109.38% |
| 2023-12-31 | $-4.73 Million | $-17.69 Million | 3.741x | +220.51% |
| 2022-12-31 | $8.30 Million | $-25.77 Million | -3.104x | -359.08% |
| 2021-12-31 | $32.44 Million | $-21.93 Million | -0.676x | +61.74% |
| 2020-12-31 | $7.04 Million | $-12.44 Million | -1.767x | -135.48% |
| 2019-12-31 | $9.36 Million | $-7.03 Million | -0.750x | -135.09% |
| 2018-12-31 | $-931.00K | $-1.99 Million | 2.139x | -- |
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid le… Read more